235 related articles for article (PubMed ID: 37528416)
1. A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation.
Javaid H; Barberis A; Chervova O; Nassiri I; Voloshin V; Sato Y; Ogawa S; Fairfax B; Buffa F; Humphrey TC
BMC Cancer; 2023 Aug; 23(1):721. PubMed ID: 37528416
[TBL] [Abstract][Full Text] [Related]
2. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
[TBL] [Abstract][Full Text] [Related]
3. Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.
Tiedemann RL; Hlady RA; Hanavan PD; Lake DF; Tibes R; Lee JH; Choi JH; Ho TH; Robertson KD
Oncotarget; 2016 Jan; 7(2):1927-46. PubMed ID: 26646321
[TBL] [Abstract][Full Text] [Related]
4. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
[TBL] [Abstract][Full Text] [Related]
5.
Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
[TBL] [Abstract][Full Text] [Related]
6. Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Tong P; Wang J; Castle EP; Stanton ML; Cheville JC; Jonasch E; Brugarolas J; Parker AS
Mod Pathol; 2016 Jan; 29(1):34-42. PubMed ID: 26516698
[TBL] [Abstract][Full Text] [Related]
7. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
Rao H; Li X; Liu M; Liu J; Feng W; Tang H; Xu J; Gao WQ; Li L
Cancer Res; 2021 Jul; 81(13):3554-3567. PubMed ID: 33910928
[TBL] [Abstract][Full Text] [Related]
8.
Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
[TBL] [Abstract][Full Text] [Related]
9. SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer.
Kumari S; Muthusamy S
Eur J Cancer Prev; 2020 Nov; 29(6):556-564. PubMed ID: 33021769
[TBL] [Abstract][Full Text] [Related]
10. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
Hu M; Hu M; Zhang Q; Lai J; Liu X
Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
[TBL] [Abstract][Full Text] [Related]
11. Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation.
Hacker KE; Fahey CC; Shinsky SA; Chiang YJ; DiFiore JV; Jha DK; Vo AH; Shavit JA; Davis IJ; Strahl BD; Rathmell WK
J Biol Chem; 2016 Sep; 291(40):21283-21295. PubMed ID: 27528607
[TBL] [Abstract][Full Text] [Related]
12. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract][Full Text] [Related]
13. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
[TBL] [Abstract][Full Text] [Related]
14. Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.
Liu W; Fu Q; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
Medicine (Baltimore); 2015 Nov; 94(45):e2004. PubMed ID: 26559293
[TBL] [Abstract][Full Text] [Related]
15. SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner.
Wang T; Wagner RT; Hlady RA; Pan X; Zhao X; Kim S; Wang L; Lee JH; Luo H; Castle EP; Lake DF; Ho TH; Robertson KD
Mol Oncol; 2024 Jan; 18(1):44-61. PubMed ID: 37418588
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms in governing genomic stability and tumor suppression by the SETD2 H3K36 methyltransferase.
Lam UTF; Chen ES
Int J Biochem Cell Biol; 2022 Mar; 144():106155. PubMed ID: 34990836
[TBL] [Abstract][Full Text] [Related]
17. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.
Kanu N; Grönroos E; Martinez P; Burrell RA; Yi Goh X; Bartkova J; Maya-Mendoza A; Mistrík M; Rowan AJ; Patel H; Rabinowitz A; East P; Wilson G; Santos CR; McGranahan N; Gulati S; Gerlinger M; Birkbak NJ; Joshi T; Alexandrov LB; Stratton MR; Powles T; Matthews N; Bates PA; Stewart A; Szallasi Z; Larkin J; Bartek J; Swanton C
Oncogene; 2015 Nov; 34(46):5699-708. PubMed ID: 25728682
[TBL] [Abstract][Full Text] [Related]
18. Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome.
El Khoury LY; Pan X; Hlady RA; Wagner RT; Shaikh S; Wang L; Humphreys MR; Castle EP; Stanton ML; Ho TH; Robertson KD
Clin Epigenetics; 2023 Apr; 15(1):71. PubMed ID: 37120552
[TBL] [Abstract][Full Text] [Related]
19. SETD2 histone modifier loss in aggressive GI stromal tumours.
Huang KK; McPherson JR; Tay ST; Das K; Tan IB; Ng CC; Chia NY; Zhang SL; Myint SS; Hu L; Rajasegaran V; Huang D; Loh JL; Gan A; Sairi AN; Sam XX; Dominguez LT; Lee M; Soo KC; Ooi LL; Ong HS; Chung A; Chow PK; Wong WK; Selvarajan S; Ong CK; Lim KH; Nandi T; Rozen S; Teh BT; Quek R; Tan P
Gut; 2016 Dec; 65(12):1960-1972. PubMed ID: 26338826
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of SETD2 promotes erastin-induced ferroptosis in ccRCC.
Xue W; Jian W; Meng Y; Wang T; Cai L; Yu Y; Yu Y; Xia Z; Zhang C
Cell Death Dis; 2023 Aug; 14(8):539. PubMed ID: 37604811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
